Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLL

2.

Which Salvage Therapy Is Best for Recurrent Prostate Cancer?

3.

Older Adults With Advanced Cancer Prioritize Quality of Life

4.

Researchers investigate risk of developing multiple primary cancers after surviving bowel cancer

5.

Novel Drug Cuts Risk for Death by 44% in Squamous Lung Cancer Trial


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot